a little more...(this is all 2 yrs old)..
Pharmaceutical Drug Discovery
Nanobac's drug discovery and development efforts are focused on applying new and existing compounds that effectively inhibit, destroy or neutralize the particles. Nanobacteria or CNPs offer a unique model for studying many diseases involving soft tissue calcification or plaque. We have developed drug screening assays using this model to screen compounds using proprietary in vitro screening assays. Compounds showing efficacy can quickly move into animal models. Our business strategy is to develop, license and commercialize compounds to address the unmet needs of patients within the cardiovascular and urological disease markets. While the Company's primary focus remains cardiovascular and urological diseases, Nanobac researchers are investigating compounds for a wide range of other therapeutic areas.
Dietary Supplements
Dietary supplement products can reach the consumer market much quicker than a new pharmaceutical product. These products use ingredients such as vitamins, minerals, herbs, or amino acids that are "Generally Regarded as Safe" (GRAS). At Nanobac Life Sciences, we apply the same approach that we use to test new pharmaceutical compounds to testing dietary supplement ingredients and formulations. Ingredients and formulations that demonstrate the desired effects can be formulated into products and then validated in clinical trials. The Company markets dietary supplements through its dietary supplement marketing arm, Nanobac Sciences, LLC. Nanobac Sciences currently markets a combination Oral Supplement and EDTA rectal suppository sold under the Nanobac Supplements brand.
Diagnostics
Nanobac Oy is a wholly owned subsidiary of Nanobac Life Sciences. Nanobac Oy Diagnostics division operates out of our Nanobac Oy facility in Kuopio, Finland. Our diagnostics division markets both in vitro diagnostic products and laboratory services.
In Vitro Diagnostic Kits and Reagents
Nanobac Oy diagnostics division manufactures and markets IVD kits and reagents for the detection of Nanobacteria or calcifying nano-particles. Products include our NanoCapture(TM) and Nano-Sero(TM) ELISA assays and our Nano-Vision(TM) line of primary monoclonal antibodies and immunohistochemical reagents. These products are marketed through a network of distributors.
Nanobac Oy Clinical Laboratory Services
Nanobac Oy Clinical Laboratory provides specialized clinical laboratory testing services to clinicians, hospitals, and laboratories. We specialize in providing advanced technologies for the detection of Nanobacteria or CNPs in human samples. Nanobac Oy Clinical Laboratory is fully accredited by the Social Health Ministry of Finland.
BioAnalytical Services
Nanobacteria or CNPs expose a risk for biopharmaceuticals containing human or animal blood components or blood and animal tissue derived raw materials or production substrates.
Nanobac BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating Nanobacteria or CNPs from raw materials or production substrates. Our contamination control program focuses on host cell lines, animal and human derived materials, raw materials, availability of diagnostic procedures and downstream processes capable of inactivating or removing contaminants.
AI
